A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus

BACKGROUND: A vaccine (HB-101) consisting of 2 nonreplicating lymphocytic choriomeningitis virus (LCMV) vectors expressing the human cytomegalovirus antigens glycoprotein B (gB) and the 65-kD phosphoprotein (pp65), respectively, is in development to prevent cytomegalovirus infection. METHODS: HB-101...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwendinger, Michael, Thiry, Georges, De Vos, Beatrice, Leroux-Roels, Geert, Bruhwyler, Jacques, Huygens, Ariane, Ganeff, Corinne, Buchinger, Heidemarie, Orlinger, Klaus K, Pinschewer, Daniel D, Monath, Thomas P, Lilja, Anders E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016443/
https://www.ncbi.nlm.nih.gov/pubmed/32313928
http://dx.doi.org/10.1093/infdis/jiaa121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016443/
https://www.ncbi.nlm.nih.gov/pubmed/32313928
http://dx.doi.org/10.1093/infdis/jiaa121

Ejemplares similares